AcelRx

Bank of New York Mellon Corp Sells 11,760 Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) | Daily Political | 6/24/2020

Bank of New York Mellon Corp decreased its holdings in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) by 4.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 232,586 shares of the specialty pharmaceutical company’s stock after selling 11,760 shares during the period. Bank of New York Mellon Corp owned about 0.29% of AcelRx Pharmaceuticals worth $274,000 as of its most recent …

By $4M, La Jolla outbids Melinta for struggling Tetraphase | 6/24/2020

… Jolla the third company in 2020 to attempt to take over the struggling antibiotic specialist. La Jolla’s bid was $4 million more than what Melinta Therapeutics offered a few weeks ago. Earlier this year, AcelRx started a bidding war with an all-shares offer that valued Tetraphase at $14 million, which it increased to $37 million after Melinta entered negotiations. The offers are a far cry from Tetraphase’s $1.8 billion …

Follow AcelRx:    

Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMT | Yahoo News | 6/23/2020

Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY Jun 23, 2020 (Thomson StreetEvents) – Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Monday, May 11, 2020 at 8:30:00pm GMT TEXT version of Transcript Corporate Participants Pamela Pierce Palmer AcelRx Pharmaceuticals, Inc. - Co-Founder, Chief Medical Officer & Director Raffi Mark Asadorian AcelRx Pharmaceuticals, Inc. - CFO Vincent J. Angotti AcelRx Pharmaceuticals, Inc. - CEO & Director Conference Call Participants Brandon Richard …

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Expected to Post Earnings of -$0.17 Per Share - TheOlympiaReport | 6/21/2020

Equities research analysts expect AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to announce earnings per share of ($0.17) for the current quarter, Zacks reports. Two analysts have made estimates for AcelRx Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.19). AcelRx Pharmaceuticals reported earnings per share of ($0.16) in the same quarter last year, which would indicate a negative year-over-year …

The FBI called a powerful opioid developed for the military a public threat. The company selling the drug says it’ll save lives. | 6/21/2020

… an accidental overdose. “Everyone would take a pill if they could,” she said, “if it worked as well and as quickly.” Excited by the prospect of being an entrepreneur, she founded her own company, AcelRx , with plans to develop and market sufentanil-based products to hospitals. For Palmer, starting her own company meant leaving a tenured university position, but Silicon Valley’s booming biotech sector beckoned. In 2009, Palmer’s quest for …

$2.81 Million in Sales Expected for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) This Quarter | Daily Political | 6/20/2020

Wall Street brokerages expect that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will report sales of $2.81 million for the current fiscal quarter, according to Zacks Investment Research . Two analysts have provided estimates for AcelRx Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $720,000.00 and the highest estimate coming in at $4.90 million. AcelRx Pharmaceuticals reported sales of $940,000.00 in the same quarter last year, which indicates a positive year …

Zacks: Analysts Anticipate AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Will Announce Earnings of -$0.17 Per Share - American Banking News | 6/18/2020

Equities research analysts forecast that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce earnings per share (EPS) of ($0.17) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for AcelRx Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.14). AcelRx Pharmaceuticals posted earnings of ($0.16) per share in the same quarter last year, which indicates a …

ACRX: New Form EFFECT for AcelRx Pharmaceuticals | 6/18/2020

New alert via PocketInfo for ACRX: New Form EFFECT for AcelRx Pharmaceuticals Press Releases: http://news.acelrx.com/phoenix.zhtml?c=241441&p=irol-acelrxnews&nyo=0 SEC Filings: http://ir.acelrx.com/phoenix.zhtml?c=241441&p=irol-sec Stock News Alerts by Pocket Info - the app Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen https://itunes.apple.com …

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) CEO Buys $10,037.51 in Stock | 6/18/2020

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) CEO Vincent J. Angotti purchased 7,547 shares of AcelRx Pharmaceuticals stock in a transaction dated Monday, June 15th. The stock was bought at an average cost of $1.33 per share, with a total value of $10,037.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink . Shares of ACRX stock opened at $1.41 on Thursday …

Insider Buying: AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Director Acquires $133,000.00 in Stock | 6/18/2020

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Director Adrian Adams acquired 100,000 shares of AcelRx Pharmaceuticals stock in a transaction dated Monday, June 15th. The shares were bought at an average cost of $1.33 per share, for a total transaction of $133,000.00. NASDAQ ACRX opened at $1.41 on Thursday. The stock has a market capitalization of $115.49 million, a PE ratio of -2.01 and a beta of 1.76. AcelRx Pharmaceuticals Inc has …

ACRX: New Form 4 for AcelRx Pharmaceuticals | 6/17/2020

New alert via PocketInfo for ACRX: New Form 4 for AcelRx Pharmaceuticals Press Releases: http://news.acelrx.com/phoenix.zhtml?c=241441&p=irol-acelrxnews&nyo=0 SEC Filings: http://ir.acelrx.com/phoenix.zhtml?c=241441&p=irol-sec Stock News Alerts by Pocket Info - the app Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen https://itunes.apple.com …

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) CEO Vincent J. Angotti Acquires 7,547 Shares | 6/16/2020

… company’s stock had a trading volume of 927,368 shares, compared to its average volume of 1,044,238. The business’s 50-day moving average price is $1.47 and its 200-day moving average price is $1.59. AcelRx Pharmaceuticals Inc has a 12 month low of $0.70 and a 12 month high of $3.02. The stock has a market cap of $104.99 million, a price-to-earnings ratio of -1.86 and a beta …

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Director Purchases $133,000.00 in Stock - American Banking News | 6/16/2020

… 1.33. 927,368 shares of the stock traded hands, compared to its average volume of 1,044,238. The company has a market cap of $104.99 million, a PE ratio of -1.90 and a beta of 1.77. AcelRx Pharmaceuticals Inc has a twelve month low of $0.70 and a twelve month high of $3.02. The firm has a 50 day simple moving average of $1.46 and a two-hundred day simple moving average …

A Director at Acelrx (ACRX) is Selling Shares | 6/16/2020

A Director at Acelrx (ACRX) is Selling Shares Carrie Williams - June 15, 2020, 9:33 PM EDT SHARE ON: Yesterday, a Director at Acelrx ( ACRX ), Adrian Adams , sold shares of ACRX for $128K. This is Adams’ first transaction since reporting a Buy transaction on AKBA back in November 2019 See today’s analyst top recommended stocks Based on Acelrx’s latest earnings report for the quarter ending March 31, the company posted quarterly …

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Director Adrian Adams Acquires 100,000 Shares - Ticker Report | 6/16/2020

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Director Adrian Adams acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were purchased at an average price of $1.33 per share, with a total value of $133,000.00. Shares of AcelRx Pharmaceuticals stock opened at $1.33 on Tuesday. AcelRx Pharmaceuticals Inc has a 12-month low of $0.70 and a 12-month high of $3.02. The …

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) CEO Vincent J. Angotti Buys 7,547 Shares of Stock | Daily Political | 6/16/2020

… stock was acquired at an average price of $1.33 per share, for a total transaction of $10,037.51. The transaction was disclosed in a filing with the SEC, which can be accessed through this link . AcelRx Pharmaceuticals stock opened at $1.33 on Tuesday. AcelRx Pharmaceuticals Inc has a 12 month low of $0.70 and a 12 month high of $3.02. The stock’s 50 day moving average is $1.46 and its 200 …

The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset | 6/10/2020

… Pharmaceuticals Inc (NASDAQ: AYLA ) Stocks In Focus Melinta Agrees To Take Tetraphase Private For $39M In Cash And $16M In CVRs With the two-way contest for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) ending after AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) pulled out, Melinta announced a definitive merger agreement to acquire Tetraphase, through a tender offer, for an aggregate of $39 million in cash, plus an additional $16 million in cash potentially …

Melinta wins bidding war to land deal to acquire Tetraphase | FierceBiotech | 6/5/2020

Melinta Therapeutics has struck a deal to buy Tetraphase Pharmaceuticals. The deal, which follows a bidding war with AcelRx Pharmaceuticals, gives Melinta another approved product and potentially complementary R&D expertise to support its bid to bounce back from bankruptcy. Tetraphase won FDA approval for the antibiotic Xerava in patients with complicated intra-abdominal infections in 2018. However, Tetraphase, like other antibiotic biotechs, has struggled to turn Xerava into a …

AcelRx Pharmaceuticals Announces It Will Not Further Revise Its Offer to Acquire Tetraphase | 6/4/2020

REDWOOD CITY, Calif. AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX ), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it does not intend to revise further its offer under the terms of its previously announced agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) (NASDAQ: TTPH ), and it expects the agreement to be terminated by Tetraphase. On June 1, 2020 …

The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck’s Triple Combo Antibiotic | 6/4/2020

… Kezar said. The stock jumped 48.32% to $6.63 in premarket trading Thursday. AcelRx Ends Bid For Tetraphase Following a bidding war for Tetraphase TTPH ) that saw the contenders sweetening their offers a few times, AcelRx ACRX ), one of the contenders, said it does not intend to revise further its offer and that the offer is likely to be terminated by Tetraphase. This leaves the path clear for a takeover of …

Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals | 6/4/2020

Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals Published: Jun 04, 2020 June 4, 2020 13:22 UTC Tetraphase terminates merger agreement with AcelRx to enter into merger agreement with Melinta Melinta agreement provides for an aggregate of $39.0 million upfront in cash plus potential contingent value rights cash payments of up to $16.0 million Acquisition Expected to Close in early Q3 2020 WATERTOWN, Mass.–( BUSINESS WIRE )– TetraPhase Pharmaceuticals , Inc. (Nasdaq: TTPH), a …

Howard Rosen Joins twoXAR Pharmaceuticals’ Board of Directors | PR Newswire | 6/3/2020

… at some of the world’s largest pharmaceutical companies, including Gilead Sciences, Inc. and ALZA Corporation, a member of the Johnson and Johnson family of companies. Mr. Rosen serves on the board of directors of AcelRx Pharmaceuticals, Inc., where he served as CEO from 2015-17, Kala Pharmaceuticals, Inc., Entrega, Inc., Metera Pharmaceuticals, Inc. and Hammerton, Inc. “We are thrilled to have Howie join our Board of Directors during this exciting time …

Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx | 6/2/2020

Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx (Ref: Business Wire) Print WATERTOWN, Mass.–( BUSINESS WIRE )– Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that its Board of Directors has received a revised proposal from Melinta Therapeutics, Inc. (“Melinta”) amending its prior proposal to …

AcelRx Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference | BioSpace | 6/2/2020

REDWOOD CITY, Calif. AcelRx Pharmaceuticals Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the Jeffries Virtual Healthcare Conference to be held June 2 at 1:30 p.m. ET ( 10:30 a.m. PT ). A live webcast link of the event can be …

20 Healthcare Stocks Moving In Tuesday’s Pre-Market Session | Benzinga | 6/2/2020

… rose 9.91% to $2.55. According to the most recent rating by Gabelli & Co., on Mar 17, the current rating is at Sell. • Cleveland BioLabs, Inc. (NASDAQ: CBLI ) stock moved upwards by 9.39% to $1.98. • AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) stock moved upwards by 8.66% to $1.38. The most recent rating by H.C. Wainwright, on Mar 17, is at Buy, with a price target of $7. • China Jo-Jo Drugstores, Inc …

Pain Management

Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMT | Yahoo News | 6/23/2020

Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY Jun 23, 2020 (Thomson StreetEvents) – Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Monday, May 11, 2020 at 8:30:00pm GMT TEXT version of … professionals are beginning to witness DSUVIA’s transformation of the acute pain management space. Dr. Palmer will now elaborate more on how DSUVIA is being used in real-world settings. Pamela Pierce Palmer, AcelRx Pharmaceuticals, Inc …

Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMT | Yahoo News | 6/23/2020

Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY Jun 23, 2020 (Thomson StreetEvents) – Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Monday, May 11, 2020 at 8:30:00pm GMT TEXT version of … professionals are beginning to witness DSUVIA’s transformation of the acute pain management space. Dr. Palmer will now elaborate more on how DSUVIA is being used in real-world settings. Pamela Pierce Palmer, AcelRx Pharmaceuticals, Inc …

Biotech

COGNOA APPOINTS SEASONED BIOTECH EXECUTIVE AS CFO | Globe Newswire | 12/2/2019

… therapeutics and digital medicines towards commercialization in 2020. Welch has an impressive 20-year track record of success guiding emerging biotech companies—managing two IPOs, as well as raising a combined total of $800M in … of care.” Prior to Eiger Pharmaceuticals, Welch was CFO at AcelRx, a specialty pharmaceutical company where he managed the company’s successful IPO and raised over $150M in support of AcelRx’s growth. At Rigel Pharmaceuticals, Jim …

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks’ Positive Readout, Enanta Misses Earnings Estimate | Benzinga | 11/22/2019

Here’s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals … Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed …

Pain Treatment

AcelRx Pharmaceuticals: Extremely Promising Risk/Reward Profile - AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) | Seeking Alpha | 10/16/2019

… for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » AcelRx Pharmaceuticals ( ACRX ) offers opioid-based medication for acute moderate-to-severe pain. Its stock … designed for usage in supervised medical facilities and for acute pain treatment only - in other words, they should not be left outside the current opioid crisis discussion that relates to chronic pain treatment based on …

After Years Of Development, AcelRx’s Dsuvia Has Finally Generated Revenue - AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) | Seeking Alpha | 5/16/2019

Last week, on Wednesday, May 8, AcelRx (NASDAQ: ACRX ) reported its financial results from the first quarter of 2019 . Though there has not been a huge amount of news to report since the company’s last … who visit the ER and receive an IV exclusively for pain treatment. Source: AcelRx March 2019 Investor Presentation AcelRx’s first step in reaching its target market is through winning formulary approvals, and the company projects …

ACO

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/6/2019

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) Q 2, 2019 Earnings Conference Call August 5, 2019 5:00 PM ET CompanyParticipants Vince Angotti - Chief Executive Officer Raffi Asadorian - Chief Financial Officer Pam Palmer - Chief Medical Officer and Co-Founder Jacob Hutchins - Anesthesiologist and Associate Professor, Department of Anesthesiology Conference CallParticipants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Ed Arce - H.C. Wainwright Chris Howerton - Jefferies Andrew D’Silva - B Riley FBR Michael Higgins …

AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain | PR Newswire | 11/16/2017

AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain News provided by 07:00 ET Share this article REDWOOD CITY, Calif. , Nov. 16, 2017 /PRNewswire/ – AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX … may lead to suboptimal outcomes for the patients,” commented Dr. Jacob Hutchins , Assistant Professor in the Department of Anesthesiology at the University of Minnesota . “This study suggests that sublingual sufentanil could provide a non-invasive …

Gilead

Howard Rosen Joins twoXAR Pharmaceuticals’ Board of Directors | PR Newswire | 6/3/2020

Gilead Sciences, Inc. and ALZA Corporation, a member of the Johnson and Johnson family of companies. Mr. Rosen serves on the board of directors of AcelRx Pharmaceuticals, Inc., where he served as CEO from 2015-17, Kala Pharmaceuticals, Inc., Entrega, Inc., Metera Pharmaceuticals, Inc. and Hammerton, Inc. “We are thrilled to have Howie join our Board of Directors during this exciting time as our discoveries advance closer to IND filings,” said …

Willis Towers Watson

INVESTOR ALERT: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal? - WLTW, TTPH, TERP | Yahoo News | 4/21/2020

… seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders: Willis Towers Watson Public Limited Company ( WLTW ) The investigation concerns whether Willis Towers and its … shareholders in connection with the proposed sale of Tetraphase to AcelRx Pharmaceuticals, Inc. for 0.6303 shares of AcelRx for each share of Tetraphase. If you are a Tetraphase shareholder and would like to learn more …

Wright Medical

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Are Shareholders Getting a Fair Deal? | PR Newswire | 4/21/2020

… seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders: Wright Medical Group N.V. (NASDAQ: WMGI ) The investigation concerns whether Wright Medical and its board … shareholders in connection with the proposed sale of Tetraphase to AcelRx Pharmaceuticals, Inc. for 0.6303 shares of AcelRx for each share of Tetraphase. If you are a Tetraphase shareholder and would like to learn more …

Pfizer

BNTX Soars On COVID-19 Alliance, DBVT Plunges, OPGN Jumps 101%, ACRX Buys TTPH | Markets Insider | Business Insider | 3/16/2020

… meeting to review DBV Technologies’ peanut allergy product, District Court ruling on Mallinckrodt’s base date AMP for Acthar Gel and AcelRx Pharma’s acquisition of Tetraphase Pharma, among others. Read on… AcelRx Pharmaceuticals Inc. (ACRX) is … 2020. BioNTech is in advanced discussions with its existing collaborator Pfizer regarding the development of the BNT162 vaccine outside China. BNTX closed Monday’s trading at $40, up 29.32%. in after-hours, the stock gained another …

Merck

Impel NeuroPharma Announces Appointment Of Adrian Adams As Chairman Of The Board Of Directors | PR Newswire | 1/9/2020

… the commercialization and development of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc. in May 2011 for $430 million . Prior to Inspire, Adrian served as … in the U.K. and currently serves as Chairman for both AcelRx Pharmaceuticals and Akebia Therapeutics. About Impel NeuroPharma Impel NeuroPharma, Inc., is a privately-held, Seattle-based biopharmaceutical company focused on developing transformative therapies for …

Jazz Pharmaceuticals

Jazz Enrolls First Patient in Phase II/III Leukemia Study | Zacks | 12/31/2019

… follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Jazz Pharmaceuticals plc ( JAZZ - Free Report ) announced that it has enrolled the first patient in … Buy). Other top-ranked stocks in the healthcare sector include AcelRx Pharmaceuticals, Inc. ( ACRX - Free Report ) , Innoviva, Inc. ( INVA - Free Report ) and Guardant Health, Inc. ( GH - Free Report ) , all sporting a Zacks Rank 1 (Strong …

Guardant Health

Jazz Enrolls First Patient in Phase II/III Leukemia Study | Yahoo News | 12/31/2019

AcelRx Pharmaceuticals, Inc. ACRX, Innoviva, Inc. INVA and Guardant Health, Inc. GH, all sporting a Zacks Rank 1 (Strong Buy). You can see the complete list of today’s Zacks 1 Rank stocks here . AcelRx Pharmaceuticals’ loss per share estimates have narrowed 6.7% for 2020 over the past 60 days. Innoviva’s earnings estimates have moved 25.2% north for 2020 over the past 60 days. Guardant Health’s loss per share estimates have …

Rockwell Medical

Is Rockwell Medical Inc (NASDAQ:RMTI) Going To Burn These Hedge Funds ? | Yahoo News | 12/23/2019

… is why following the smart money sentiment is a useful tool at identifying the next stock to invest in. Is Rockwell Medical Inc (NASDAQ: RMTI ) a healthy stock for your portfolio? Money managers are getting … similarly valued. These stocks are Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ), AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ), Hi-Crush Inc. (NYSE: HCR ), and Ohio Valley Banc Corp. (NASDAQ: OVBC ). This group of stocks’ market valuations is similar …

Biogen

Neurological Disorder Drugs Market Active Status, Growth Opportunities, Forecast to 2027 – Neurocrine Biosciences, Pfizer, Biogen, Teva, AcelRx, Eli Lilly, Adamas, BioMarin, AstraZeneca, Novartis | 12/3/2019

Press Releases Neurological Disorder Drugs Market Active Status, Growth Opportunities, Forecast to 2027 – Neurocrine Biosciences, Pfizer, Biogen, Teva, AcelRx, Eli Lilly, Adamas, BioMarin, AstraZeneca, Novartis Neurological Disorders are associated with dysfunction in any part of the brain or nervous system resulting in physical or psychological damage. Various types of neurological drugs are available in the market such as antipsychotic, antiepileptic, anticholinergic and analgesics for the treatments of neurological disorders. The …

Allergan

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical’s Earnings Beat | Benzinga | 11/12/2019

… for developing it as a combo therapay along with Urogen’s UGN-201 for high-grade non-muscle invasive bladder cancer) Allergan plc (NYSE: AGN ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Cabaletta Bio Inc (NASDAQ: CABA ) Centogene … Dumps (Biotech stocks hitting 52-week lows on Nov. 11) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX )(Credit Suisse downgraded shares to Neutral) Achieve Life Sciences Inc (NASDAQ: ACHV ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Applied DNA …

PDL BioPharma

PDL BioPharma Reports 2019 Third Quarter Financial Results | PR Newswire | 11/6/2019

INCLINE VILLAGE, Nev. PDL BioPharma, Inc. (“PDL” or “the Company”) (Nasdaq: PDLI ) reports financial results for the three and nine months ended September 30, 2019 : Third Quarter Financial Highlights Total revenues were $44.2 million , including … is primarily related to a non-cash adjustment to the AcelRx royalty asset fair value of negative $60.0 million in the second quarter of 2019. PDL received $58.3 million in net cash royalties from its …

Bristol-Myers Squibb

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek’s Mixed Clinical Readout, CareDx Slips On Guidance | Benzinga | 11/1/2019

… Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) AstraZeneca plc (NYSE: AZN ) Bristol-Myers Squibb Co (NYSE: BMY )( reported better-than-expected third-quarter results) Celgene Corporation … Dumps (Biotech Stocks Hitting 52-week lows on Oct. 31) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO )(reported below-consensus third-quarter earnings) Alimera Sciences Inc (NASDAQ …

Teladoc

3 Stocks Peter Lynch Would Love | Yahoo News | 4/29/2019

AcelRx Pharmaceuticals (NASDAQ: ACRX) , Teladoc (NYSE: TDOC) , and Bristol-Myers Squibb (NYSE: BMY) . Read on to find out more about these outstanding growth vehicles. A rising stack of coins leading up to a jar fill of hundred dollar bills. A green upward trending arrow hovers above the stack of coins. More Image source: Getty Images. A potential multibagger George Budwell (AcelRx Pharmaceuticals): Peter Lynch’s multipronged investing strategy essentially boils down …

Cantor Fitzgerald

Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMT | Yahoo News | 6/23/2020

AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY Jun 23, 2020 (Thomson StreetEvents) – Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Monday, May 11, 2020 at 8:30:00pm GMT TEXT version of Transcript Corporate Participants Pamela Pierce Palmer AcelRx Pharmaceuticals, Inc. - Co-Founder, Chief Medical Officer & Director Raffi Mark Asadorian AcelRx Pharmaceuticals, Inc. - CFO Vincent J. Angotti AcelRx Pharmaceuticals, Inc. - CEO & Director Conference Call Participants Brandon Richard Folkes Cantor …

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/6/2019

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) Q 2, 2019 Earnings Conference Call August 5, 2019 5:00 PM ET CompanyParticipants Vince Angotti - Chief Executive Officer Raffi Asadorian - Chief Financial Officer Pam Palmer - Chief Medical Officer and Co-Founder Jacob Hutchins - Anesthesiologist and Associate Professor, Department of Anesthesiology Conference CallParticipants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Ed Arce - H.C. Wainwright Chris Howerton - Jefferies Andrew D’Silva - B Riley FBR Michael Higgins …

Stryker

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Are Shareholders Getting a Fair Deal? | PR Newswire | 4/21/2020

… securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Wright Medical to Stryker Corporation for $30.75 per share. If you are a Wright Medical shareholder and would … shareholders in connection with the proposed sale of Tetraphase to AcelRx Pharmaceuticals, Inc. for 0.6303 shares of AcelRx for each share of Tetraphase. If you are a Tetraphase shareholder and would like to learn more …

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Are Shareholders Getting a Fair Deal? | PR Newswire | 4/21/2020

… securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Wright Medical to Stryker Corporation for $30.75 per share. If you are a Wright Medical shareholder and would … shareholders in connection with the proposed sale of Tetraphase to AcelRx Pharmaceuticals, Inc. for 0.6303 shares of AcelRx for each share of Tetraphase. If you are a Tetraphase shareholder and would like to learn more …

Legg Mason

TTPH, TCO, LM, and WLTW SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers | Globe Newswire | 3/24/2020

… regarding possible breaches of fiduciary duties and other violations of law related to Tetraphase Pharmaceuticals’ agreement to be acquired by AcelRx Pharmaceuticals, Inc. Shareholders of Tetraphase Pharmaceuticals will receive 0.6303 shares of AcelRx Pharmaceuticals and … and your rights, visit: https://www.rigrodskylong.com/cases-taubman-centers-inc . Legg Mason, Inc. (NYSE: LM ) regarding possible breaches of fiduciary duties and other violations of law related to Legg Mason’s agreement to be acquired by …

TTPH, TCO, LM, and WLTW SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers | Globe Newswire | 3/24/2020

… regarding possible breaches of fiduciary duties and other violations of law related to Tetraphase Pharmaceuticals’ agreement to be acquired by AcelRx Pharmaceuticals, Inc. Shareholders of Tetraphase Pharmaceuticals will receive 0.6303 shares of AcelRx Pharmaceuticals and … and your rights, visit: https://www.rigrodskylong.com/cases-taubman-centers-inc . Legg Mason, Inc. (NYSE: LM ) regarding possible breaches of fiduciary duties and other violations of law related to Legg Mason’s agreement to be acquired by …

Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) Stock Moves -1.14%: What You Should Know | Zacks | 1/28/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article AcelRx Pharmaceuticals ( ACRX - Free Report ) closed at $1.73 in the latest trading session, marking a -1.14% move from the prior day. This change was narrower than the S&P 500’s daily loss of 1.57%. Meanwhile, the Dow lost 1.57%, and the …

Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study | Zacks | 1/7/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Soleno Therapeutics, Inc. ( SLNO - Free Report ) announced that it … the same sector include Pacira BioSciences, Inc. ( PCRX - Free Report ) , AcelRx Pharmaceuticals, Inc. ( ACRX - Free Report ) and Corcept Therapeutics Incorporated ( CORT - Free Report ) , all sporting a Zacks Rank 1 (Strong Buy). You can see the …

RBC Capital Markets

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/6/2019

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) Q 2, 2019 Earnings Conference Call August 5, 2019 5:00 PM ET CompanyParticipants Vince Angotti - Chief Executive Officer Raffi Asadorian - Chief Financial Officer Pam Palmer - Chief Medical Officer and Co-Founder Jacob Hutchins - Anesthesiologist and Associate Professor, Department of Anesthesiology Conference CallParticipants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Ed Arce - H.C. Wainwright Chris Howerton - Jefferies Andrew D’Silva - B Riley FBR Michael Higgins …

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/9/2019

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Chief Medical Officer Conference Call Participants Dan Busby - RBC Capital Markets Brandon Folkes - Cantor Fitzgerald Vamil Divan - Credit Suisse Michael Higgins - Ladenburg Thalman Andrew D’Silva - B Riley FBR Aryeh Gold - Oppenheimer Operator Welcome to the AcelRx First Quarter 2019 Conference …

Viscogliosi Brothers

PDL BioPharma’s Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide | PR Newswire | 11/8/2017

AcelRx, University of Michigan , Viscogliosi Brothers and Depomed. PDL’s equity and loan investments in Noden represent deployed and committed capital of $179.0 million and $202.0 million , respectively, and its converted equity and loan investment in LENSAR represents deployed capital of $40 million . NOTE: PDL, PDL BioPharma, the PDL logo and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary, to PDL BioPharma, Inc. which reserves all …

PDL BioPharma’s Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process | PR Newswire | 11/8/2017

AcelRx, University of Michigan , Viscogliosi Brothers and Depomed. PDL’s equity and loan investments in Noden represent deployed and committed capital of $179.0 million and $202.0 million , respectively, and its converted equity and loan investment in LENSAR represents deployed capital of $40 million . NOTE: PDL, PDL BioPharma, the PDL logo and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary, to PDL BioPharma, Inc. which reserves all …

Wilson Medical Center

Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMT | Yahoo News | 6/23/2020

Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY Jun 23, 2020 (Thomson StreetEvents) – Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Monday, May 11, 2020 at 8:30:00pm GMT TEXT version of … is the Chairman of Surgery and Director of Trauma at Wilson Medical Center, a United Health Services Hospital, who will share his experience with DSUVIA. Before we begin, I’ll remind listeners that during this call …

Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMT | Yahoo News | 6/23/2020

Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY Jun 23, 2020 (Thomson StreetEvents) – Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Monday, May 11, 2020 at 8:30:00pm GMT TEXT version of … is the Chairman of Surgery and Director of Trauma at Wilson Medical Center, a United Health Services Hospital, who will share his experience with DSUVIA. Before we begin, I’ll remind listeners that during this call …

United Health Services

Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMT | Yahoo News | 6/23/2020

Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY Jun 23, 2020 (Thomson StreetEvents) – Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Monday, May 11, 2020 at 8:30:00pm GMT TEXT version of … Surgery and Director of Trauma at Wilson Medical Center, a United Health Services Hospital, who will share his experience with DSUVIA. Before we begin, I’ll remind listeners that during this call, we will make forward …

Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMT | Yahoo News | 6/23/2020

Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY Jun 23, 2020 (Thomson StreetEvents) – Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Monday, May 11, 2020 at 8:30:00pm GMT TEXT version of … Surgery and Director of Trauma at Wilson Medical Center, a United Health Services Hospital, who will share his experience with DSUVIA. Before we begin, I’ll remind listeners that during this call, we will make forward …

Brigham and Women's Hospital

Stryker employee potentially has COVID-19 & more: 10 device company notes | Beckers Spine Review | 3/18/2020

AcelRx Pharmaceuticals is partnering with Brigham and Women’s Hospital in Boston to study the perioperative use of DSUVIA in the analgesic regimen for spine surgery. The FDA provided Medacta clearance for its Mecta-C Stand Alone anterior cervical fusion device. A royalties dispute between Medtronic and Carmel-based Indiana Spine Group founder Rick Sasso, MD, was returned to a state court March 4. Osteobiologics company Biogennix received FDA clearance March …

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results | PR Newswire | 3/16/2020

REDWOOD CITY, Calif. AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full … with procurement recommendation expected post-meeting. Announced an agreement with Brigham and Women’s Hospital for an investigator-initiated study led by Richard D. Urman MD, MBA, Associate Professor of Anesthesia and co-director of the …

Harvard Medical School

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results | PR Newswire | 3/16/2020

REDWOOD CITY, Calif. AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full … Center for Perioperative Research at Brigham and Women’s Hospital and Harvard Medical School . The study plans to examine the perioperative use of DSUVIA in the analgesic regimen for spine surgery. Financial Information Cash, cash equivalents …

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results | PR Newswire | 3/16/2020

REDWOOD CITY, Calif. AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full … Center for Perioperative Research at Brigham and Women’s Hospital and Harvard Medical School . The study plans to examine the perioperative use of DSUVIA in the analgesic regimen for spine surgery. Financial Information Cash, cash equivalents …

Hennepin County Medical Center

AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department | PR Newswire | 11/9/2017

AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department News provided by 07:00 ET Share this article REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire … commented Dr. James Miner , Chief of Emergency Medicine at the Hennepin County Medical Center. “The use of sufentanil sublingual tablets is particularly promising as it could lead to more efficient acute pain treatment, thereby potentially …

AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets | PR Newswire | 11/9/2017

REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire/ – AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported … commented Dr. James Miner , Chief of Emergency Medicine at the Hennepin County Medical Center. “The use of sufentanil sublingual tablets is particularly promising as it could lead to more efficient acute pain treatment, thereby potentially …

Leiden University Medical Center

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … University Hospitals in Philadelphia, PA; Albert Dahan, MD, PhD, Professor, Leiden University Medical Center in Leiden, Netherlands; and Dennis Fisher, MD, Professor Emeritus, University of California, San Francisco. Time/Place: 6:30 am – 8:00 am on …

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … University Hospitals in Philadelphia, PA; Albert Dahan, MD, PhD, Professor, Leiden University Medical Center in Leiden, Netherlands; and Dennis Fisher, MD, Professor Emeritus, University of California, San Francisco. Time/Place: 6:30 am – 8:00 am on …

University Hospital

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … Dynamics of Sublingual Sufentanil Authors: Eugene Viscusi, MD, Professor, Jefferson University Hospitals in Philadelphia, PA; Albert Dahan, MD, PhD, Professor, Leiden University Medical Center in Leiden, Netherlands; and Dennis Fisher, MD, Professor Emeritus, University of …

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … Dynamics of Sublingual Sufentanil Authors: Eugene Viscusi, MD, Professor, Jefferson University Hospitals in Philadelphia, PA; Albert Dahan, MD, PhD, Professor, Leiden University Medical Center in Leiden, Netherlands; and Dennis Fisher, MD, Professor Emeritus, University of …

University Medical Center

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … Hospitals in Philadelphia, PA; Albert Dahan, MD, PhD, Professor, Leiden University Medical Center in Leiden, Netherlands; and Dennis Fisher, MD, Professor Emeritus, University of California, San Francisco. Time/Place: 6:30 am – 8:00 am on October …

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … Hospitals in Philadelphia, PA; Albert Dahan, MD, PhD, Professor, Leiden University Medical Center in Leiden, Netherlands; and Dennis Fisher, MD, Professor Emeritus, University of California, San Francisco. Time/Place: 6:30 am – 8:00 am on October …

Vince Angotti

Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMT | Yahoo News | 6/23/2020

Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY Jun 23, 2020 (Thomson StreetEvents) – Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Monday, May 11, 2020 at 8:30:00pm GMT TEXT version of … the Investors section of our website. With me today are Vince Angotti, our Chief Executive Officer; and Dr. Pam Palmer, our Chief Medical Officer. Also on the call with us today is Dr. Christian Tvetenstrand …

Gina M. Serra

Rigrodsky & Long, P.A. Files Class Action Suit Against Tetraphase Pharmaceuticals, Inc. | Yahoo News | 4/30/2020

… Tetraphase Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (NASDAQ: TTPH ) common stock in connection with the proposed acquisition of Tetraphase by AcelRx Pharmaceuticals, Inc. (“AcelRx”) and Consolidation Merger Sub, Inc. (“Merger Sub”), announced on March 16 … or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A. , 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, by telephone at (888) 969-4242, by e-mail at , or …

Seth D. Rigrodsky

Rigrodsky & Long, P.A. Files Class Action Suit Against Tetraphase Pharmaceuticals, Inc. | Yahoo News | 4/30/2020

… Tetraphase Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (NASDAQ: TTPH ) common stock in connection with the proposed acquisition of Tetraphase by AcelRx Pharmaceuticals, Inc. (“AcelRx”) and Consolidation Merger Sub, Inc. (“Merger Sub”), announced on March 16 … notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A. , 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, by telephone at (888) 969-4242, by …

Daniel Sadeh

INVESTOR ALERT: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal? - WLTW, TTPH, TERP | Yahoo News | 4/21/2020

… federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Tetraphase to AcelRx Pharmaceuticals, Inc. for 0.6303 shares of AcelRx for each share of Tetraphase. If you … charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] . Halper Sadeh LLP represents investors all over the world who …

Pamela Palmer

AcelRx Announces Agreement for an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Spine Surgery | PR Newswire | 3/6/2020

REDWOOD CITY, Calif. , March 6, 2020 /PRNewswire/ – AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an agreement … an effective level of analgesia for the patient,” said Dr. Pamela Palmer , Co-Founder and Chief Medical Officer at AcelRx Pharmaceuticals. “By supporting investigator-initiated studies by highly respected institutions, such as Brigham and Women’s …

Jacob Hutchins

AcelRx Pharmaceuticals Inc (ACRX) Q2 2019 Earnings Call Transcript | Yahoo News | 8/6/2019

Logo of jester cap with thought bubble. More Image source: The Motley Fool. AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) Q2 2019 Earnings Call Aug 5, 2019 , 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call … Medical Officer. Also with us today is an anesthesiologist, Dr. Jacob Hutchins, who will share his experience with using DSUVIA in the University of Minnesota Ambulatory Surgery Center. Before we begin, I’ll remind listeners that …

Michael Higgins

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/6/2019

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) Q 2, 2019 Earnings Conference Call August 5, 2019 5:00 PM ET CompanyParticipants Vince Angotti - Chief Executive Officer Raffi Asadorian - Chief Financial Officer Pam Palmer - Chief Medical Officer and Co-Founder Jacob Hutchins - Anesthesiologist and Associate Professor, Department of Anesthesiology Conference CallParticipants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Ed Arce - H.C. Wainwright Chris Howerton - Jefferies Andrew D’Silva - B Riley FBR Michael Higgins

Peter Lynch

3 Stocks Peter Lynch Would Love | Yahoo News | 4/29/2019

Peter Lynch is widely regarded as one of the best investors of all time, and for good reason. During his 13-year tenure at the Fidelity Magellan Fund, Lynch grew a modest $20 million into … rundown for their top Peter Lynch-like picks. They named AcelRx Pharmaceuticals (NASDAQ: ACRX) , Teladoc (NYSE: TDOC) , and Bristol-Myers Squibb (NYSE: BMY) . Read on to find out more about these outstanding growth vehicles. A …

James Miner

AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department | PR Newswire | 11/9/2017

AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department News provided by 07:00 ET Share this article REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire … several limitations with the current treatment options available,” commented Dr. James Miner , Chief of Emergency Medicine at the Hennepin County Medical Center. “The use of sufentanil sublingual tablets is particularly promising as it could lead …

John P. McLaughlin

PDL BioPharma’s Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide | PR Newswire | 11/8/2017

… will not extend the deadline for, or otherwise alter, its proposal. In reaching the decision to not extend the deadline, John P. McLaughlin , chief executive officer of PDL, said, “We continue to believe our proposal … committed capital of $396.1 million and $397.1 million , respectively: KYBELLA®, AcelRx, University of Michigan , Viscogliosi Brothers and Depomed. PDL’s equity and loan investments in Noden represent deployed and committed capital of $179.0 million and $202.0 …

Karen DiDonato

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … Meeting. The information presented during the session was authored by Karen DiDonato , MSN, RN; Jacob Hutchins , MD; James Miner , MD; Harold Minkowitz , MD; and Pamela Palmer , MD, PhD. “We are honored to be one of …

Harold Minkowitz

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … Karen DiDonato , MSN, RN; Jacob Hutchins , MD; James Miner , MD; Harold Minkowitz , MD; and Pamela Palmer , MD, PhD. “We are honored to be one of the top eight abstracts featured as an oral presentation at …

Eugene Viscusi

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … of sublingual sufentanil tablets. This symposium will be led by Eugene Viscusi , MD; Albert Dahan , MD, PhD; and Dennis Fisher , MD. The ANESTHESIOLOGY ® 2017 Annual Meeting is hosted by the American Society of Anesthesiologists (ASA …

Albert Dahan

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … tablets. This symposium will be led by Eugene Viscusi , MD; Albert Dahan , MD, PhD; and Dennis Fisher , MD. The ANESTHESIOLOGY ® 2017 Annual Meeting is hosted by the American Society of Anesthesiologists (ASA) and is taking …

Dennis Fisher

AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 | PR Newswire | 10/20/2017

Worldwide Offices AcelRx’s DSUVIA™ Clinical Trial Results Selected as a “Top Abstract” for Oral Presentation at ASA’s Annual Meeting - ANESTHESIOLOGY® 2017 DSUVIA clinical trial results was one of the top eight abstracts featured as an … led by Eugene Viscusi , MD; Albert Dahan , MD, PhD; and Dennis Fisher , MD. The ANESTHESIOLOGY ® 2017 Annual Meeting is hosted by the American Society of Anesthesiologists (ASA) and is taking place on October 21-25 in …